Dysregulated ILC metabolism contributes to immune evasion in tumors and to pathogenic activation in autoimmune diseases such as inflammatory bowel disease (IBD) and systemic lupus erythematosus (SLE). This evidence concerns the gene CCL27 and autoimmune disease.